ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
Duke2
|
44 |
12K |
0 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
44
|
12K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
Duke2
|
474 |
153K |
6 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
474
|
153K
|
6
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Trading Halt
|
|
Duke2
|
21 |
6.6K |
2 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
21
|
6.6K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Trading Halt
|
|
Duke2
|
21 |
6.6K |
6 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
21
|
6.6K
|
6
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Duke2
|
125 |
25K |
1 |
14/04/24 |
14/04/24 |
ASX - By Stock
|
125
|
25K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
Duke2
|
89 |
32K |
5 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
89
|
32K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: AACR Conference Presentation
|
|
Duke2
|
7 |
1.4K |
3 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
7
|
1.4K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
Duke2
|
89 |
32K |
2 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
89
|
32K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
Duke2
|
89 |
32K |
5 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
89
|
32K
|
5
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
Duke2
|
89 |
32K |
3 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
89
|
32K
|
3
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Final Director's Interest Notice MB
|
|
Duke2
|
16 |
5.8K |
1 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
16
|
5.8K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
Duke2
|
89 |
32K |
1 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
89
|
32K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
Duke2
|
89 |
32K |
1 |
01/04/24 |
01/04/24 |
ASX - By Stock
|
89
|
32K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
Duke2
|
44 |
12K |
1 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
44
|
12K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Duke2
|
670 |
252K |
5 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
670
|
252K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
Duke2
|
44 |
12K |
1 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
44
|
12K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Update on ACCENT Trial in Pancreatic Cancer
|
|
Duke2
|
44 |
12K |
0 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
44
|
12K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Duke2
|
58 |
14K |
2 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
58
|
14K
|
2
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD to present at NWR Virtual Healthcare Conference
|
|
Duke2
|
3 |
1.6K |
1 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
3
|
1.6K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Duke2
|
58 |
14K |
3 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
58
|
14K
|
3
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Investor Presentation
|
|
Duke2
|
11 |
3.3K |
1 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
11
|
3.3K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Duke2
|
58 |
14K |
0 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
58
|
14K
|
0
|
|
ASX - By Stock
|
IBX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Duke2
|
113 |
41K |
0 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
113
|
41K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Duke2
|
58 |
14K |
3 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
58
|
14K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
Duke2
|
89 |
32K |
2 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
89
|
32K
|
2
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Corporate Presentation
|
|
Duke2
|
118 |
25K |
0 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
118
|
25K
|
0
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Corporate Presentation
|
|
Duke2
|
118 |
25K |
0 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
118
|
25K
|
0
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Corporate Presentation
|
|
Duke2
|
118 |
25K |
1 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
118
|
25K
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Corporate Presentation
|
|
Duke2
|
118 |
25K |
2 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
118
|
25K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Duke2
|
670 |
252K |
6 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
670
|
252K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
where are we at at the moment ?
|
|
Duke2
|
40 |
14K |
5 |
09/03/24 |
09/03/24 |
ASX - By Stock
|
40
|
14K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Final Director's Interest Notice
|
|
Duke2
|
19 |
5.7K |
5 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
19
|
5.7K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Final Director's Interest Notice
|
|
Duke2
|
19 |
5.7K |
5 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
19
|
5.7K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Duke2
|
58 |
14K |
0 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
58
|
14K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
Duke2
|
89 |
32K |
3 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
89
|
32K
|
3
|
|
ASX - By Stock
|
AGN |
Re:
Anything under a cheeky dollar this is a steal
|
|
Duke2
|
36 |
10K |
1 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
36
|
10K
|
1
|
|
ASX - By Stock
|
AGN |
Re:
Anything under a cheeky dollar this is a steal
|
|
Duke2
|
36 |
10K |
3 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
36
|
10K
|
3
|
|
ASX - By Stock
|
AGN |
Re:
General Discussions
|
|
Duke2
|
96 |
33K |
11 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
96
|
33K
|
11
|
|
ASX - By Stock
|
IBX |
Re:
Ann: Appendix 4E and Preliminary Final Report
|
|
Duke2
|
10 |
5.0K |
4 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
10
|
5.0K
|
4
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Pilot Study Validates RAD Terbium-161 Radiotherapeutics
|
|
Duke2
|
6 |
1.5K |
0 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
6
|
1.5K
|
0
|
|
ASX - By Stock
|
1AD |
Re:
Countdown on to Adalta Trial Results
|
|
Duke2
|
85 |
16K |
1 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
85
|
16K
|
1
|
|
ASX - By Stock
|
IBX |
Re:
Ann: Imagion Business Update
|
|
Duke2
|
12 |
8.0K |
4 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
12
|
8.0K
|
4
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Pilot Study Validates RAD Terbium-161 Radiotherapeutics
|
|
Duke2
|
6 |
1.5K |
1 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
6
|
1.5K
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Countdown on to Adalta Trial Results
|
|
Duke2
|
85 |
16K |
0 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
85
|
16K
|
0
|
|
ASX - By Stock
|
AGN |
Re:
Anything under a cheeky dollar this is a steal
|
|
Duke2
|
36 |
10K |
2 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
36
|
10K
|
2
|
|
ASX - By Stock
|
AGN |
Re:
Anything under a cheeky dollar this is a steal
|
|
Duke2
|
36 |
10K |
2 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
36
|
10K
|
2
|
|
ASX - By Stock
|
AGN |
Re:
General Discussions
|
|
Duke2
|
96 |
33K |
0 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
96
|
33K
|
0
|
|
ASX - By Stock
|
AGN |
Re:
General Discussions
|
|
Duke2
|
96 |
33K |
1 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
96
|
33K
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Countdown on to Adalta Trial Results
|
|
Duke2
|
85 |
16K |
1 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
85
|
16K
|
1
|
|
ASX - By Stock
|
AGN |
Re:
General Discussions
|
|
Duke2
|
96 |
33K |
6 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
96
|
33K
|
6
|
|